Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer
Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd),